{"doi":"10.1016/j.intimp.2024.111919","title":"PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration","abstract":null,"journal":"International Immunopharmacology","year":2024,"id":625302,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1616910,"name":"Justyna Sakowska","orcid":null,"position":1,"is_corresponding":false},{"id":1616911,"name":"Dorota Iwaszkiewicz-Grześ","orcid":null,"position":2,"is_corresponding":false},{"id":1616912,"name":"Mateusz Gliwiński","orcid":null,"position":3,"is_corresponding":false},{"id":1616913,"name":"Matylda Hennig","orcid":null,"position":4,"is_corresponding":false},{"id":1616914,"name":"Magdalena Żalińska","orcid":null,"position":5,"is_corresponding":false},{"id":1616915,"name":"Anna Wołoszyn-Durkiewicz","orcid":null,"position":6,"is_corresponding":false},{"id":1616916,"name":"Anna Jaźwińska-Curyłło","orcid":null,"position":7,"is_corresponding":false},{"id":1616917,"name":"Halla Kamińska","orcid":null,"position":8,"is_corresponding":false},{"id":1616918,"name":"Radosław Owczuk","orcid":null,"position":9,"is_corresponding":false},{"id":973831,"name":"Wojciech Młynarski","orcid":"0000-0003-2714-5851","position":10,"is_corresponding":false},{"id":1616919,"name":"Przemysława Jarosz-Chobot","orcid":null,"position":11,"is_corresponding":false},{"id":1616920,"name":"Artur Bossowski","orcid":null,"position":12,"is_corresponding":false},{"id":978366,"name":"Agnieszka Szadkowska","orcid":"0000-0002-8281-4408","position":13,"is_corresponding":false},{"id":951140,"name":"Wojciech Fendler","orcid":"0000-0002-5083-9168","position":14,"is_corresponding":false},{"id":1616921,"name":"Iwona Beń-Skowronek","orcid":null,"position":15,"is_corresponding":false},{"id":750023,"name":"Agata Chobot","orcid":"0000-0002-9622-4433","position":16,"is_corresponding":false},{"id":978367,"name":"Małgorzata Myśliwiec","orcid":"0000-0002-1533-8544","position":17,"is_corresponding":false},{"id":1616923,"name":"Janusz Siebert","orcid":null,"position":18,"is_corresponding":false},{"id":1616924,"name":"Natalia Marek-Trzonkowska","orcid":null,"position":19,"is_corresponding":false},{"id":1616925,"name":"Piotr Trzonkowski","orcid":"0000-0001-5287-5210","position":20,"is_corresponding":false},{"id":1616909,"name":"Maciej Zieliński","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration","abstract":"An imbalance between exaggerated autoaggressive T cell responses, primarily CD8 + T cells, and impaired tolerogenic mechanisms underlie the development of type 1 diabetes mellitus. Disease-modifying strategies, particularly immunotherapy focusing on FoxP3 + T regulatory cells (Treg), and B cells facilitating antigen presentation for T cells, show promise. Selective depletion of B cells may be achieved with an anti-CD20 monoclonal antibody (mAb). In a 2-year-long flow cytometry follow-up, involving 32 peripheral blood T and B cell markers across three trial arms (Treg + rituximab N = 12, Treg + placebo N = 13, control N = 11), we observed significant changes. PD-1 receptor (+) CD4 + Treg, CD4 + effector T cells (Teffs), and CD8 + T cell percentages increased in the combined regimen group by the end of follow-up. Conversely, the control group exhibited a notable reduction in PD-1 receptor (+) CD4 + Teff percentages. Considering clinical endpoints, higher PD-1 receptor (+) expression on T cells correlated with positive responses, including a higher mixed meal tolerance test AUC, and reduced daily insulin dosage. PD-1 receptor (+) T cells emerged as a potential therapy outcome biomarker. In vitro validation confirmed that successful Teff suppression was associated with elevated PD-1 receptor (+) Treg levels. These findings support PD-1 receptor (+) T cells as a reliable indicator of treatment with combined immunotherapy consisting of Tregs and anti-CD20 mAb efficacy in type 1 diabetes mellitus.","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38554443","pmcid":null,"openalex_id":"https://openalex.org/W4393341974","authors":[],"funders":[{"funder_name":"Horizon 2020","grant_id":"","title":null},{"funder_name":"Medical Research Agency","grant_id":"","title":null}],"total_grants":2,"fwci":2.1914,"citation_percentile":0.87915655,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":9},{"year":2026,"count":4}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1567576924004375?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1567576924004375?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.intimp.2024.111919","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38554443","host_type":"repository"}],"fields_of_study":["Immune Cell Function and Interaction","Diabetes and associated disorders","T-cell and B-cell Immunology"],"mesh_terms":["Rituximab","Adolescent","Child","Diabetes Mellitus, Type 1","Female","Humans","Male","Treatment Outcome","T-Lymphocytes, Regulatory","Programmed Cell Death 1 Receptor"],"keywords":["FOXP3","IL-2 receptor","Immunology","CD8","Immunotherapy","Medicine","T cell","Regulatory T cell","CD20","Cytotoxic T cell","Antigen","Internal medicine","Biology","Immune system","In vitro","type 1 diabetes","PD-1","Regulatory T cells","Rituximab","Cell-based Therapy","Immune-tolerance"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T06:23:11.740852Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}